News Ipsen's Cabometyx recommended by NICE for previously treated... French drugmaker Ipsen’s Cabometyx (cabozantinib) has been recommended by the National Institute for Health and Care
News UK says it has hit target on commercial trial set-up times The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
